Next 10 |
home / stock / cmndf / cmndf news
VANCOUVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated h...
The first episode, "Psychedelic Novelty - Before it was Cool," introduces the company's proprietary molecule MEAI VANCOUVER, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind ” or the " company ...
VANCOUVER, Sept. 25, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind ” or the " Company "), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertr...
Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd. VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind ” or the " ...
TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announc...
VANCOUVER, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind ” or the " C ompany "), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major un...
The dedicated treatment indicated a significant decrease in cocaine craving in a sub- group that received Clearmind's MEAI VANCOUVER, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind ...
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat d...
Psychedelic drug developer Clearmind Medicine ( OTCPK:CMNDF ) ( OTC:CMND ) has filed to raise up to $14M through a US initial public offering. The Canadian company filed to offer an undisclosed number of units , with each unit consisting of one share plus one warrant to ...
Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board VANCOUVER, June 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“ Clearmind ” or the " Company "), a ...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated h...
The first episode, "Psychedelic Novelty - Before it was Cool," introduces the company's proprietary molecule MEAI VANCOUVER, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind ” or the " company ...
VANCOUVER, Sept. 25, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind ” or the " Company "), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertr...